We observed that CCAAT/enhancer-binding protein (C/EBP)a is highly inducible in primary fibroblasts by DNA-damaging agents that induce strand breaks, alkylate and crosslink DNA as well as those that produce bulky DNA lesions. Fibroblasts deficient in C/EBPa (C/EBPa À/À ) display an impaired G 1 checkpoint as evidenced by an inappropriate entry into the S-phase in response to DNA damage, and these cells also display an enhanced G 1 /S transition in response to mitogens. The induction of C/EBPa by DNA damage in fibroblasts does not require p53. Electrophoretic mobility shift assay (EMSA) analysis of nuclear extracts prepared from ultraviolet B (UVB)-and N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG)-treated fibroblasts showed increased binding of C/EBPb to a C/EBP consensus sequence and chromatin immunoprecipitation (ChIP) analysis also showed increased C/EBPb binding to the C/EBPa promoter. To determine whether C/EBPb has a function in the regulation of C/EBPa, we treated C/EBPb À/À fibroblasts with UVB or MNNG. We observed that C/EBPa induction was impaired in both UVB-and MNNG-treated C/EBPb À/À fibroblasts. Our study shows a novel function for C/EBPb in the regulation of C/EBPa in response to DNA damage and provides definitive genetic evidence that C/EBPa has a critical role in the DNA damage G 1 checkpoint.
Introduction
The CCAAT/enhancer-binding proteins (C/EBPs) are members of the basic leucine zipper (bZIP) class of transcription factors that contain a C-terminal basic DNA-binding domain and a leucine zipper domain involved in homo-or hetero-dimerization (Ramji and Foka, 2002) . The N-terminal region contains transcription activation and regulatory domains that interact with basal transcription apparatus and transcription co-activators. There are six members of the C/EBP family and C/EBPs have important functions in fundamental cellular processes, including proliferation, apoptosis, differentiation, inflammation, senescence and energy metabolism (Ramji and Foka, 2002; Johnson, 2005) .
C/EBPa mediates cell-cycle arrest associated with terminal differentiation in adipocytes (Umek et al., 1991; Lin and Lane, 1994) , hepatocytes (Diehl et al., 1996) and myeloid cells (Radomska et al., 1998; Wang et al., 1999) and it regulates the expression of genes associated with the differentiated phenotype in these cell types. Consistent with its role in the regulation of differentiation, C/EBPa has been shown to be a tumor suppressor gene in acute myeloid leukemia, in which it is inactivated in B9% of AML cases through specific somatic mutations (Pabst et al., 2001; Gombart et al., 2002) . The inactivating mutations in C/EBPa result in a block in granulocytic differentiation and contribute to the uncontrolled proliferation of undifferentiated immature granulocytic blasts. Ectopic or forced expression of C/EBPa inhibits cell-cycle progression in nearly all cell types examined (Hendricks-Taylor and Darlington, 1995; Watkins et al., 1996; Halmos et al., 2002; Johnson, 2005; Shim et al., 2005) ; however, the intrinsic cellular signals and pathways that regulate C/EBPa expression and its growth arrest properties are not fully understood. In some cases, these pathways are linked to cellular differentiation. C/EBPa expression is ablated or greatly diminished in a number of epithelial cancers, including lung (Halmos et al., 2002) , skin (Oh and Smart, 1998; Shim et al., 2005) , liver , head and neck (Bennett et al., 2007) , endometrial (Takai et al., 2005) and breast , suggesting a tumor suppressor function. In many cases, the C/EBPa gene is silenced through promoter hypermethylation Tada et al., 2006; Bennett et al., 2007) . Causal or genetic evidence for a suppressor role of C/EBPa in epithelial tumorigenesis is lacking because of the absence of C/EBPa mutations in epithelial tumors. Moreover, genetically engineered mouse models to document the suppressor function of C/EBPa in tumorigenesis have been problematic as germ line or lung-specific deletion of C/EBPa is perinatally lethal (Wang et al., 1995; Basseres et al., 2006) . Recently, a genetically engineered mouse model in which C/EBPa was ablated in the epidermis was successfully developed (Loomis et al., 2007) . These mice survived and were highly susceptible to carcinogen-induced skin tumorigenesis, thus providing the first genetic evidence for C/EBPa as a suppressor of epithelial tumorigenesis. Surprisingly, the epidermalspecific C/EBPa knockout mice did not show alterations in stratified squamous differentiation or proliferation of epidermal keratinocytes, suggesting that their enhanced susceptibility to tumorigenesis is not related to alterations in keratinocyte differentiation (Loomis et al., 2007) .
To prevent or reduce stress-induced injury and cellular damage, cells have evolved intricate pathways that permit them to respond to both intrinsic and extrinsic stressors. In terms of DNA damage, cells respond by engaging cell-cycle checkpoints and repairing damaged DNA in order to maintain genome integrity and to prevent heritable mutations, which can lead to genomic instability, aging and cancer (Kastan and Bartek, 2004; Sancar et al., 2004; Ishikawa et al., 2006) . In ultraviolet B (UVB)-treated skin keratinocytes, C/EBPa expression is highly induced through a p53dependent pathway and the partial small interfering RNA (siRNA) knockdown of C/EBPa in the BALB/ MK2 keratinocyte cell line resulted in a diminished G 1 checkpoint after UVB-induced DNA damage (Yoon and Smart, 2004) . Although C/EBPa was highly induced by UVB in keratinocytes, UVB treatment of HepG2, NRK and NIH3T3 cells failed to induce C/EBPa. Thus, C/EBPa, at least in keratinocytes, is regulated by stress involving DNA damage through a p53 pathway, and it appears to have a role in the maintenance of genomic stability through its role in the G 1 checkpoint. However, genetic evidence supporting a role for C/EBPa in the G 1 checkpoint is lacking, and as mentioned above, no other cell types other than keratinocytes have been reported to respond to DNA damage with the induction of C/EBPa.
In light of C/EBPa's role in tumorigenesis and DNA damage response, it is important to understand the stress pathways or mechanisms through which C/EBPa is regulated in response to DNA damage and the functional importance of C/EBPa's induction. In this study, we show that fibroblasts respond to multiple types of DNA damage with the induction of C/EBPa, and we present genetic evidence using C/EBPa À/À cells to show a role for C/EBPa in the G 1 checkpoint. Importantly, we have identified a novel stress pathway, in which C/EBPb has a role in the induction of C/EBPa in response to DNA damage.
Results
UVB induces C/EBPa in fibroblasts and C/EBPa À/À fibroblasts display alterations in the G 1 /S transition and G 1 checkpoint Initially, we attempted cell-cycle studies in wild-type and C/EBPa À/À primary keratinocytes; however, these studies were not informative because of the inherent complexity of using primary keratinocytes for cell-cycle regulation studies owing to the presence of mixed populations of differentiating and proliferating primary keratinocytes. To provide direct genetic evidence for C/EBPa in the G 1 checkpoint and to extend the findings on UVB-induced expression of C/EBPa in keratinocytes to another cell type, mouse dermal wild-type and C/EBPa À/À primary fibroblasts were used. Wild-type and C/EBPa À/À primary fibroblasts were exposed to a single dose of UVB radiation (5 mJ/cm 2 ). UVB radiation produced a significant increase in C/EBPa protein levels in wild-type fibroblasts ( Figure 1a ) and C/EBPa was not expressed in C/EBPa À/À fibroblasts (Figure 1b ). In wild-type fibroblasts, C/EBPa was maximally induced at 6 h post UVB treatment and returned to control levels by 24 h post UVB treatment. Elevated levels of C/EBPa were detected as early as 1 h post UVB treatment (data not shown). UVB also induced a modest transient increase in C/EBPb at 6 h post UVB treatment ( Figure 1a ).
To examine the effect of the genetic ablation of C/EBPa on cell-cycle regulation, wild-type and C/EBPa À/À and primary fibroblasts were synchronized by serum deprivation and then released into the cell cycle by the addition of serum-containing media. Fibroblasts were either left untreated or treated with a single dose of UVB (5 mJ/cm 2 ) 4 h after release. Cells were pulsed with 5-bromo-2 0 -deoxyuridine (BrdU) 1 h before each collection time point (4, 15, 18, 21 and 24 h post release) and fluorescence-activated cell sorting Figure 1 Ultraviolet B (UVB) radiation induces C/EBPa in primary fibroblasts and C/EBPa is involved in the G 1 /S transition as well as in UVB-induced G 1 checkpoint. (a) Primary fibroblasts were exposed to UVB (5 mJ/cm 2 ), and cell lysates were prepared at various time points and immunoblot analysis was conducted. Nonspecific (NS) band is shown to confirm equal loading. (b) Primary fibroblasts from newborn wild-type or C/EBPa À/À were treated with UVB (5 mJ/cm 2 ), and cell lysates were prepared at various time points and immunoblot analysis was conducted. (c and d) Wild-type (open column) and C/EBPa À/À (black column) fibroblasts were synchronized by serum deprivation for 28 h in 0.5% serum and then released into the cell cycle by the addition of serum-containing medium. Fibroblasts were either not treated (c) or treated with UVB (5 mJ/cm 2 ) (d) at 4 h after the addition of serum-containing medium. Cells were pulse labeled with 5-bromo-2 0 -deoxyuridine (BrdU) 1 h before collection, and then the cells were fixed, incubated with anti-BrdU antibody, stained with propidium iodine (PI) and subjected to FACS analysis. The number above each column pair represents the percentage increase in S-phase cells in C/EBPa À/À fibroblasts compared with wild type. Data represent mean±s.d (N ¼ 3 per time point per genotype). Two-factor ANOVA showed significant interaction between genotype and time for both untreated and treated cells (Po0.05). Significantly different from wild-type fibroblasts (*Po0.05) at the indicated time point as determined by Student's t-test. C/EBPa is regulated by C/EBPb in response to DNA damage R Ranjan et al (FACS) analysis was conducted to monitor entry into Sphase. Serum-released C/EBPa À/À and wild-type fibroblasts not treated with UVB displayed a synchronized entry into S-phase. However, C/EBPa À/À fibroblasts consistently displayed 10-20% more cells in S-phase than wild-type fibroblasts, indicating that C/EBPa À/À cells have an enhanced mitogen-induced entry into S-phase (Figures 1c and e ). Serum-released C/EBPa À/À and wild-type fibroblasts treated with UVB showed a significant decrease in the number of S-phase cells at 15 and 18 h compared with untreated control cells and this decrease was followed by a recovery at 21 and 24 h, indicating that cells from both genotypes engaged a G 1 checkpoint response. However, UVBtreated C/EBPa À/À fibroblasts showed a significantly attenuated G 1 checkpoint, as there were B70% more DNA damage and the regulation of C/EBPa As shown in Figure 2a , UVB treatment of fibroblasts with a dose of 5, 10 and 20 mJ/cm 2 resulted in the induction of C/EBPa, with the higher doses displaying a more prolonged induction of C/EBPa. To determine whether C/EBPa can be induced by DNA-damaging agents other than UVB, we treated fibroblasts with N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG), a direct acting mutagen that methylates DNA; cisplatin, a cancer therapeutic that crosslinks DNA; camptothecin, an alkaloid with antitumor activity that induces singlestranded DNA breaks by inhibiting topoisomerase I enzyme; and bleomycin, an anti-neoplastic drug that induces both single-and double-stranded DNA breaks. As shown in Figures 2b-e, MNNG, cisplatin, camptothecin and bleomycin were inducers of C/EBPa.
To determine whether the increases in UVB-induced C/EBPa protein levels involve altered stability of C/EBPa protein, untreated and UVB-treated fibroblasts were incubated with cycloheximide, an inhibitor of protein synthesis, and the stability of the C/EBPa protein was examined over time. The degradation of C/EBPa protein was similar in both untreated (Figure 2f , left panel) and UVB-treated fibroblasts (Figure 2f , right panel). Similar results were observed for C/EBPb (Figure 2f ). To determine whether C/EBPa mRNA levels are increased by UVB treatment, we used TaqMan quantitative reverse transcription-PCR (qRT-PCR). UVB treatment (5 mJ/cm 2 ) of primary fibroblast resulted in significant increases in C/EBPa mRNA level at 6 and 12 h post UVB treatment (Figure 2g ), and this increase was blocked by actinomycin D, an inhibitor of transcription (data not shown). These results indicate that the increased levels of C/EBPa in UVB-treated fibroblasts are due to increased transcription of C/EBPa. In keratinocytes, the transcription factor p53 is essential for the UVB induction of C/EBPa (Yoon and Smart, 2004) . As shown in Figure 3a , UVB treatment of wild-type primary keratinocytes resulted in significant increases in the protein levels of C/EBPa and p53, as C/EBPa is regulated by C/EBPb in response to DNA damage well as in the p53 target gene p21, whereas UVB treatment of p53 À/À primary keratinocytes failed to significantly induce the expression of both C/EBPa and p21 protein ( Figure 3a) . These results verify that in keratinocytes, p53 is required for C/EBPa induction by UVB. In contrast to keratinocytes, p53 was dispensable for the UVB induction of C/EBPa in fibroblasts. As shown in Figure 3b , UVB treatment of p53 À/À fibroblasts efficiently induced C/EBPa and as anticipated failed to induce the p53 target, p21, thus verifying the ablation of p53 activity (Figure 3b ). These results indicate that p53 is dispensable for the UVB induction of C/EBPa in fibroblasts, indicating a p53-independent pathway that contributes to the induction of C/EBPa in fibroblasts.
UVB increases C/EBPb binding to C/EBP consensus sequence and is bound to the C/EBPa promoter During the process of L1 pre-adipocyte differentiation, both C/EBPb protein levels and DNA-binding activity are increased, and C/EBPb has been shown to regulate C/EBPa levels during process (Christy et al., 1991; Darlington et al., 1998; Tang et al., 1999 Tang et al., , 2004 . Because we observed that UVB produces an increase in C/EBPb protein levels, we initiated studies to examine whether C/EBPb has a function in the regulation of C/EBPa expression in response to DNA damage. First, we used electrophoretic mobility shift assay (EMSA) analysis to examine whether nuclear extracts isolated from UVBand MNNG-treated fibroblasts display increases in the binding of C/EBPb to a canonical C/EBP consensus sequence (TGCAGATTGCGCAATCTGCA) (Osada et al., 1996) . As shown in Figure 4a , nuclear extracts from cells treated with UVB and MNNG displayed increased C/EBP binding to the C/EBP consensus sequence, and this increase appeared somewhat greater than the increase in C/EBPa and C/EBPb protein levels (Figure 4a , lower panel). As shown in Figure 4b , no binding was detected with these nuclear extracts when a mutant C/EBP consensus sequence (TGCAGAGAC TAGTCTCTGCA) was used, and in competition studies, only the cold wild-type C/EBP consensus sequence could compete for binding. Supershift assays with antibodies to C/EBPa and C/EBPb, but not IgG control antibodies, showed that the increase in C/EBP DNA binding post UVB was due to both C/EBPa and C/EBPb binding with C/EBPb that was present in all complexes (Figure 4c ). Owing to alternative translation start sites, C/EBPb protein can be present in three isoforms, termed LAP* (liver-activating protein*); LAP aka C/EBPb and LIP (liver inhibitory protein), which functions as a dominant-negative inhibitor of LAP*; and LAP. To begin to understand which C/EBPb isoforms are responsible for the increased binding in the EMSA analysis, we first conducted immunoblot analysis of protein extracts from fibroblasts to examine the levels of the three C/EBPb isoforms and then overexpressed LAP and LIP and examined their DNA binding location using EMSA. As shown in Figure 4d , LAP is the predominate C/EBPb isoform in fibroblasts and is also the predominate C/EBPb-binding isoform in UVB-treated fibroblasts (Figure 4e ). As shown in Figure 4f , we also conducted EMSA analysis using the C/EBP-binding sequence 5 0 -(À188) GCGTTGCGCC ACGATCTCTC (À169)-3 0 , which was previously identified as a bona fide C/EBP site in the C/EBPa promoter (Tang et al., 1999 (Tang et al., , 2004 . We observed increases in C/EBP binding after UVB or MNNG treatment to the C/EBPa promoter consensus oligomer (Figure 4f ), which is similar to those observed using the canonical C/EBP consensus sequence (Figure 4a ). This binding could compete with cold consensus sequence (data not shown). To determine whether the C/EBPb binds to this C/EBP site in the C/EBPa promoter in vivo, we conducted chromatin immunoprecipitation (ChIP) analysis using a C/EBPb antibody to immunoprecipitate C/EBPb-DNA complexes. PCR was performed on the input DNA and C/EBPb-immunoprecipitated DNA with primers that flank the C/EBP site in the C/EBPa promoter. We observed that C/EBPb was bound to the C/EBPa promoter in the basal untreated state and that UVB treatment consistently produced a modest increase in C/EBPb binding (N ¼ 3) at the early time point (Figure 4g ). To further confirm the specificity of immunoprecipitation of C/EBPb, we carried out ChIP analysis on the C/EBPa promoter in C/EBPb À/À fibroblasts. We observed an absence of a PCR product in the C/EBPb-immunoprecipitated samples, further supporting our results that C/EBPb directly binds to the C/EBPa promoter in wild-type fibroblasts. We also conducted ChIP analysis on the C/EBPa promoter with a C/EBPa antibody to determine whether C/EBPa is bound to its own promoter in vivo. We observed that C/EBPa is bound to its own promoter at the basal state Figure 3 Ultraviolet B (UVB) induction of C/EBPa does not require p53 in fibroblasts. (a) Primary keratinocytes were isolated from wild-type (WT) and p53 À/À newborn mice and were treated with UVB (10 mJ/cm 2 ). Keratinocytes were harvested at the indicated time points and immunoblot analysis was conducted.
(b) Primary fibroblasts isolated from WT and p53 À/À newborn mice were treated with UVB (10 mJ/cm 2 ). Fibroblasts were harvested at indicated time points and immunoblot analysis was conducted.
and UVB treatment resulted in increased C/EBPa binding (Figure 4h ). Taken together, these results suggest that C/EBPa expression is regulated by C/EBPb in response to DNA damage and that C/EBPa has an autoregulatory role.
C/EBPb has a role in the UVB and MNNG induction of C/EBPa
To determine whether C/EBPb has a functional role in the regulation of C/EBPa in response to DNA damage, we isolated dermal fibroblasts from wild-type and C/EBPb À/À mice and treated these cells with UVB (5 or 10 mJ/cm 2 ) or MNNG (35 mM). As shown in Figure 5a , UVB (10 mJ/cm 2 ) induction of C/EBPa protein in C/EBPb À/À fibroblasts was impaired, as both the level of protein induction was reduced and the time course for its induction was altered. Although the induction of C/EBPa was impaired, the increase in p53 protein was comparable in wild-type and C/EBPb À/À fibroblasts (Figure 5a ). The induction of C/EBPa was also impaired in C/EBPb À/À fibroblasts treated with a lower dose of UVB (5 mJ/cm 2 ) ( Figure 5b ) or with the alkylating mutagen, MNNG (Figure 5c ). To determine whether C/EBPb deficiency has an effect on UVBinduced C/EBPa mRNA levels, we isolated RNA from wild-type and C/EBPb À/À fibroblasts before and after UVB treatment and examined C/EBPa mRNA levels using TaqMan qRT-PCR (Figure 5d ). The UVB induction of C/EBPa mRNA was significantly decreased Figure 4 Ultraviolet B (UVB) and N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG) increase binding of C/EBPa and C/EBPb to the C/EBP consensus sequence and to the C/EBPa promoter in vivo. (a) Wild-type (WT) fibroblasts were treated with UVB (5 mJ/cm 2 ) or MNNG (35 mM) and nuclear extracts were prepared. Electrophoretic mobility shift assay (EMSA) was conducted with 2 mg of nuclear extract and a labeled WT C/EBP consensus oligonucleotide probe. (Lower panel) Nuclear extract from above experiment was used to conduct immunoblot analysis. (b) WT fibroblasts were treated with UVB (5 mJ/cm 2 ) and nuclear extracts were prepared. EMSA was conducted with 2 mg of nuclear extract and a labeled WT or mutant C/EBP consensus oligonucleotide probe. Competition assays were performed with cold WT or cold mutant (MT) C/EBP probe (50-fold in excess). (c) WT fibroblasts were treated with UVB (5 mJ/cm 2 ) and nuclear extracts were prepared. EMSA was conducted with 2 mg of nuclear extract and a labeled WT C/EBP consensus oligonucleotide probe. Supershift assays were performed with anti-C/EBPa, anti-C/EBPb antibody or IgG (SS-Supershift). (d) Primary fibroblasts from WT and C/EBPb À/À mice were treated with UVB (5 mJ/cm 2 ). Cells were harvested at the indicated time points and immunoblot analysis was conducted. (e) Nuclear extracts were prepared from non-treated and UVB (5 mJ/cm 2 ) treated fibroblasts (lanes 1 and 2) and from HEK 293 cells transfected with pcDNA3.1-C/EBPb-LAP or pcDNA3.1-C/EBPb-LIP (lanes 3 and 4). EMSA was conducted with 2 mg of nuclear extract and a labeled C/EBP consensus oligonucleotide probe. (f) WT fibroblasts were treated with UVB (5 mJ/cm 2 ) or MNNG (35 mM) and nuclear extracts were prepared at indicated time points. EMSA was conducted with 2 mg of nuclear extract and a labeled C/EBP consensus sequence corresponding to the C/EBP responsive element in the C/EBPa promoter. (g) WT or C/EBPb À/À fibroblasts were treated with UVB (5 mJ/cm 2 ), and ChIP assay using a C/EBPb antibody was conducted as described in the Materials and methods section. Input control represents 5% DNA as compared with IgG or C/EBPb samples. (h) WT fibroblasts were treated with UVB (5 mJ/cm 2 ), and ChIP assay using a C/EBPa antibody was conducted as described in the Materials and methods section. Input control represents 5% DNA as compared with IgG or C/EBPa samples. in C/EBPb À/À fibroblasts compared with that in wildtype fibroblasts (Figure 5d ). Collectively, these results indicate that in fibroblasts, C/EBPb functions downstream of DNA damage to partially regulate C/EBPa mRNA and protein expression.
Discussion
Earlier we have shown that C/EBPa is a UVB/DNA damage-inducible gene in mouse and human primary keratinocytes; however, UVB treatment did not induce C/EBPa in three other cell lines examined (HepG2, NRK or NIH3T3 cells) (Yoon and Smart, 2004 ), suggesting the induction of C/EBPa by UVB may be a keratinocytes-specific effect. In keratinocytes, UVB induction of C/EBPa is solely dependent on p53, and this is mediated through p53 binding to a p53 response element in the distal promoter of C/EBPa (Yoon and Smart, 2004) . The results presented in this study indicate that C/EBPa is a DNA damage-responsive gene in mouse primary fibroblasts and that p53 is dispensable for the UVB induction of C/EBPa in fibroblasts. Instead, we observed that C/EBPa is regulated by C/EBPb in response to DNA damage and C/EBPa likely has an autoregulatory role in response to DNA damage. C/EBPa induction by DNA damage was impaired in C/EBPb À/À fibroblasts, both at the protein and mRNA levels and the time course for their induction was altered; however, there was not a complete ablation of C/EBPa induction, indicating that other pathways are also involved. Although C/EBPb has been shown to regulate C/EBPa expression during preadipocyte differentiation (Christy et al., 1991; Darlington et al., 1998; Tang et al., 1999 Tang et al., , 2004 , to the best of our knowledge, our study is the first to show that C/EBPb functions downstream of DNA damage to regulate the induction of C/EBPa. Therefore, C/EBPb is a protein that can be activated by numerous cues, including those involving differentiation (Yeh et al., 1995; Sterneck et al., 1997; Oh and Smart, 1998; Zhu et al., 1999) and DNA damage (Ewing et al., 2008) , as well as oncogenes (Sundfeldt et al., 1999; Rask et al., 2000; Zhu et al., 2002; Shuman et al., 2004) and inflammatory cytokines (Akira et al., 1990; Mukaida et al., 1990; Drouet et al., 1991) . Recently, Ewing et al. (2008) reported that C/EBPb represses p53 levels and function to promote cell survival downstream of DNA damage. Therefore, emerging evidence indicate that both C/EBPa and C/EBPb participate in DNA damage response pathways.
UVB treatment produced a modest increase in C/EBPb levels, and ChIP analyses also showed modest increases in C/EBPb binding to the C/EBPa promoter, and yet C/EBPb À/À fibroblasts displayed a significantly impaired induction of C/EBPa mRNA and protein in response to UVB or MNNG treatment. Our ChIP results also showed that C/EBPb is constitutively bound (a-c) Primary fibroblasts from newborn wild type (WT) or C/EBPb À/À mice were treated with UVB (10 mJ/cm 2 ), UVB (5 mJ/cm 2 ) or N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG) (35 mM). Cells were harvested at the indicated time points and immunoblot analysis was conducted. (d) Primary fibroblasts from newborn WT or C/EBPb À/À mice were treated with UVB (5 mJ/cm 2 ) and RNA isolated at the indicated time points. Quantitative RT-PCR was conducted for C/EBPa and 18S mRNA levels. Data were normalized using 18S and was analyzed using the comparative C T method. Data are expressed as mean ± standard error (N ¼ 4) and each experiment was run in triplicate. Two-factor ANOVA showed significant interaction between genotype and time (Po0.05). Significantly different from WT fibroblasts (*Po0.05) at the indicated time point as determined by Student's t-test.
to the C/EBPa promoter in untreated fibroblasts. Taken together, these results suggest that post-translational modifications of C/EBPb may contribute to the regulation of C/EBPa in response to UVB. It is generally accepted that C/EBPb exists in a repressed state and, post-translational modifications de-repress C/EBPb and increase its transcriptional activity. For example, phosphorylation or deletion of the repressor domain unfolds and induces conformational change in C/EBPb, which results in de-repression and increased transactivation activity of C/EBPb (Kowenz-Leutz et al., 1994; Williams et al., 1995) . In addition to phosphorylation, C/EBPb is modified by acetylation and a mutant C/EBPb that can no longer be acetylated on Lys-39 has an impaired ability to transactivate a C/EBPa promoter reporter construct (Cesena et al., 2007 (Cesena et al., , 2008 . Post-translational modifications involving methylation (Pless et al., 2008) and sumoylation (Kim et al., 2002; Eaton and Sealy, 2003; Berberich-Siebelt et al., 2006) also have regulatory roles, and changes in the mediator complex result in C/EBPb activation (Mo et al., 2004) .
Recently, it was reported that C/EBPb is involved in the opening of chromatin, allowing other transcription factors to bind to the gene promoter and increase gene expression (Plachetka et al., 2008) . Further studies are required to understand how C/EBPb is activated in response to DNA damage and how these events contribute to the regulation of C/EBPa. Previous studies in keratinocytes using siRNA knockdown of C/EBPa indicated that C/EBPa has a role in the G 1 checkpoint in response to DNA damage (Yoon and Smart, 2004) . One goal of this study was to use a genetic approach to confirm and verify the role of C/EBPa in the G 1 checkpoint as siRNA knockdown studies can be complicated by the unintentional interaction of the siRNA with other unidentified targets. We observed a diminished G 1 checkpoint response in C/EBPa À/À fibroblasts compared with wild-type fibroblasts in response to UVB treatment, and our results provide important genetic evidence that C/EBPa is involved in DNA damage-induced G 1 checkpoint. Moreover, we observed that serum-deprived C/EBPa À/À fibroblasts display an enhanced mitogeninduced entry into S-phase compared with wild-type fibroblasts, suggesting that C/EBPa has a direct role in the regulation of the G 1 /S transition in response to mitogens. To our knowledge, there are no previous studies that have used synchronous cultures of primary cells genetically deficient in C/EBPa to define a functional role for C/EBPa in the regulation of G 1 /S transition in response to mitogens. Proposed mechanisms for C/EBPa-induced cell-cycle arrest involve interactions with cell-cycle proteins, including Rb family members (Chen et al., 1996; Timchenko et al., 1999) , CDK4 and CDK2 , E2F (Slomiany et al., 2000; Porse et al., 2001) , p21 (Timchenko et al., 1996) and the SWI/SNF chromatin remodeling complex (Muller et al., 2004) . Further studies are required to understand the molecular mechanisms of C/EBPa's involvement in the G 1 /S transition and how this impinges on the DNA damage-induced G 1 checkpoint and neoplasia.
Materials and methods
Cell lines and cell culture Mouse primary keratinocytes were isolated from the epidermis of newborn mice by overnight flotation of skin in trypsin at 4 1C (Hennings et al., 1980; Dlugosz et al., 1995) and dermal fibroblasts were isolated from the dermis after the removal of the epidermis from skin. Primary keratinocytes were cultured as described by Yoon and Smart (2004) . For fibroblasts isolation, the dermis was subjected to digestion in collagenase (0.35%) for 25 min, followed by DNase (250 U per skin sample) treatment for 5 min at 37 1C while shaking. Cells were filtered and collected after centrifugation, and isolated fibroblasts were plated in Eagle's minimal essential medium (BioWhittaker, Walkersville, MD, USA) (2 mM CaCl 2 ) supplemented with 10% fetal bovine serum (Sigma, St Louis, MO, USA), 100 U/ml of penicillin, 100 mg/ml of streptomycin and 0.25 mg/ml of amphotericin B (Gibco-Invitrogen, Carlsbad, CA, USA) in a 100-mm tissue culture dish. Upon confluence, fibroblasts were passaged and plated in a 60-mm tissue culture dish. When cells reached 70% confluence, they were treated with UVB or other DNA-damaging agents.
Animals
Germline C/EBPa À/À mice do not survive; pups die prenatally or survive only few hours after birth (Wang et al., 1995) . A keratin 5-Cre, K5Cre, transgenic mouse line is used for generalized Cremediated recombination or tissue-specific gene ablation. When floxed females carrying transgene K5Cre are mated with floxed male animals, recombination occurs in all the tissues in all mice produced from the above mating pair (Ramirez et al., 2004) . Germline C/EBPa À/À pups were produced by mating epidermal conditional C/EBPa À/À female (K5Cre;C/EBPa fl/fl ) (C57BL/ 6;DBA;129SV) (Loomis et al., 2007) with C/EBPa floxed (C/ EBPa fl/fl ) male mice (C57BL/6;DBA;129SV) (Lee et al., 1997) . Primers and PCR conditions used to genotype mice were published previously (Lee et al., 1997; Ramirez et al., 2004) . p53 þ /À male mice were mated with p53 þ /À female mice to generate p53 À/À as well as wild-type newborn pups (C57BL/6). Primers and PCR conditions were published previously (Hulla et al., 2001) . The C/EBPb À/À mice used in this study have been described previously (Sterneck et al., 1997) . The C/EBPb À/À and wild-type new born pups were generated by mating C/EBPb þ /À females with C/EBPb þ /À males (C57BL/6;129/SV). For all other studies not using genetically modified mice, fibroblasts were isolated from the dermis of wild-type 129SV mice.
Treatment of cells
The UV lamp (model EB 280C; Spectronics, Westbury, NY, USA) used for treating cells emits wavelengths between 280 and 320 nm with a spectrum peak at 312 nm. The intensity of light emitted was measured by NIST Traceable Radiometer Photometer (Model IL1400A, International Light Technologies, Peabody, MA, USA). Cells were treated with UVB as described by Yoon and Smart (2004) . MNNG, camptothecin and cycloheximide were dissolved in dimethyl sulfoxide. Cisplatin (cis-Diammineplatinum (II)) and bleomycin were dissolved in water. Cells were treated with MNNG, cycloheximide, camptothecin, bleomycin, dimethyl sulfoxide or water. Cells were treated with cisplatin for 2 h, and then media was replaced with fresh media without cisplatin. Actinomycin D was dissolved in ethanol and cells were treated with actinomycin D or ethanol.
Preparation of cell lysates
Nuclear extracts were prepared as previously described by Schreiber et al. (1989) . For preparation of whole-cell lysates, cells were washed with cold phosphate-buffered saline and harvested by scraping. Cells were collected by centrifugation and protein was isolated in radioimmunoprecipitation assay buffer as previously described (Ewing et al., 2008) .
Western blot analysis
Protein from cell lysates was loaded onto a 12% polyacrylamide Tris-glycine gel (Invitrogen, Carlsbad, CA, USA), then separated by electrophoresis and transferred to an Immobilon-P membrane (Millipore, Billerica, MA, USA). After incubation in a blocking buffer (Oh and Smart, 1998) , the membranes were probed with rabbit polyclonal immunoglobulin G (IgG) raised against C/EBPa (sc-61), p53 (sc-6243), C/EBPb (sc-150), p21 (sc-757) or mouse monoclonal raised against a-tubulin (sc-8035) (1:2000) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and then probed with a horseradish peroxidaselinked secondary antibody (Amersham, GE Healthcare, Piscataway, NJ, USA). Detection was carried out with an enhanced chemiluminescence reagent (Perkin-Elmer Life Science, Waltham, MA, USA) followed by exposure of the membrane to the film.
Quantitative real-time PCR
Total RNA was isolated from either control or UVB-treated fibroblasts using TRI reagent (Sigma) and then purified by the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). cDNA was prepared from 50 ng RNA by ImProm-II Reverse Transcription System (Promega, Madison, WI, USA) following as per the manufacturer's protocol. cDNA was used to perform quantitative PCR using mouse C/EBPa TaqMan Gene Expression Assays, 18S TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) and TaqMan Universat PCR mix (Applied Biosystems). Data were analyzed using the comparative C T method.
ChIP assay
Primary fibroblasts were plated in 100 mm culture plates and were left untreated or treated with UVB dose of 5 mJ/cm 2 . After 1 and 6 h of UVB treatment, cells were treated with 1% formaldehyde, and thereafter ChiP assay was performed as per the manufacturer's instruction (Upstate Biotechnology, Millipore, Billerica, MA, USA). The formaldehyde-treated cells were lysed with SDS lysis buffer and sonicated to produce 200-500 bp long DNA fragments. Samples were pre-cleared with salmon sperm DNA/protein A, and then immunoprecipitated with polyclonal antibody against C/EBPb, C/EBPa or rabbit IgG at 4 1C overnight. Immunoprecipitated DNA was decrosslinked with 5 M NaCl and extracted by ethanol/chloroform precipitation and amplified by PCR. Primer set for PCR was designed to flank the C/EBP regulatory sequence in the C/ EBPa promoter 5 0 -(À188) GCGTTGCGCCACGATCTCTC (À169)-3 0 (Tang et al., 1999 (Tang et al., , 2004 . Primer set flanking the corresponding site were 5 0 -(À324) GGCTGGAAGTGGGT GACTTA (À305)-3 0 and 5 0 -(À115) CGCCTTCTCCTGT GACTTTC (À134)-3 0 to produce a 210-bp PCR product.
EMSA and supershift
Nuclear extracts, 2 mg in 10 ml buffer C, were incubated with 10 ml of master binding mix buffer with 32 P-labeled C/EBP probe (Santa Cruz Biotechnology) or 32 P-labeled probe corresponding to the C/EBP-responsive element in the C/EBPa promoter for 30 min at room temperature. For the supershift assays, samples were treated as above but incubated with C/EBPa (sc-61), C/EBPb (sc-150) or IgG (sc-2027) (Santa Cruz Biotechnology) antibody. For competition assays, samples were incubated for 20 min with cold wild-type and cold mutant C/EBP consensus oligonucleotide probe (50-fold in excess) in 10 ml master mix binding buffer and then with wild-type 32 P-labeled C/EBP probe for 20 min at room temperature. Samples were loaded onto 6% polyacrylamide gel and subjected to electrophoresis in 0.025 Â TBE buffer at 200 V for 5-7 h at 4-8 1C.
BrdU labeling and FACS analysis
When fibroblasts reached 30-40% confluence, cells were synchronized by serum deprivation in 0.5% fetal bovine serum for 28 h. Fibroblasts were released by adding 10% fetal bovine serum containing fibroblast medium. After 4 h of release, fibroblasts were either left untreated or treated with UVB (5 mJ/cm 2 ). One hour before, the cells were harvested at each time point, and were incubated with 10 mM BrdU. Cells were then fixed in 70% alcohol, treated with 2 N HCl-Triton X-100 to denature DNA, followed by neutralization with Na 2 B 4 O 7 . Cells were pelleted, resuspended in 0.5% Tween 20-1% bovine serum albumin-phosphate-buffered saline with anti-BrdUfluorescein isothiocyanate antibody (1:50; Becton Dickinson, Franklin Lakes, NJ, USA) and 0.5 mg of RNase per ml, and incubated at 4 1C overnight. Cells were pelleted and resuspended in phosphate-buffered saline containing 5 mg/ml of propidium iodide (PI) and subjected to FACS analysis.
